PRA-216 COPD Safety and Biomarker Study
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age40-80
SponsorPrana Therapies Inc
About this trial
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Eligibility criteria
Qualifiers
Age 40-80
Willing and able to attend all study visits, comply with study requirements.
Able and willing to provide written informed consent
Documented COPD diagnosis prior for at least 12 months prior to screening.
Disqualifiers
Evidence of clinically significant pulmonary condition or disease other than COPD
Any physical or psychological condition that prohibits study completion
Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism within 12 months prior to the first dose of study agent
History of severe allergic reactions or hypersensitivity
Trial design
Treatments tested in this trial
- PRA-216
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov